company background image
CELZ logo

Creative Medical Technology Holdings NasdaqCM:CELZ Stock Report

Last Price

US$2.96

Market Cap

US$4.0m

7D

-6.6%

1Y

-39.0%

Updated

02 Oct, 2024

Data

Company Financials +

Creative Medical Technology Holdings, Inc.

NasdaqCM:CELZ Stock Report

Market Cap: US$4.0m

CELZ Stock Overview

A commercial stage biotechnology company, focuses on novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics in the United States.

CELZ fundamental analysis
Snowflake Score
Valuation2/6
Future Growth5/6
Past Performance0/6
Financial Health6/6
Dividends0/6

Creative Medical Technology Holdings, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Creative Medical Technology Holdings
Historical stock prices
Current Share PriceUS$2.96
52 Week HighUS$10.28
52 Week LowUS$2.65
Beta5.04
11 Month Change-14.94%
3 Month Change-22.00%
1 Year Change-38.97%
33 Year Change-96.05%
5 Year Change-99.55%
Change since IPO-100.00%

Recent News & Updates

Recent updates

Shareholder Returns

CELZUS BiotechsUS Market
7D-6.6%-0.2%-0.4%
1Y-39.0%22.1%34.1%

Return vs Industry: CELZ underperformed the US Biotechs industry which returned 22.1% over the past year.

Return vs Market: CELZ underperformed the US Market which returned 34.1% over the past year.

Price Volatility

Is CELZ's price volatile compared to industry and market?
CELZ volatility
CELZ Average Weekly Movement10.4%
Biotechs Industry Average Movement10.0%
Market Average Movement6.4%
10% most volatile stocks in US Market14.9%
10% least volatile stocks in US Market3.1%

Stable Share Price: CELZ's share price has been volatile over the past 3 months.

Volatility Over Time: CELZ's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
n/a4Tim Warbingtonwww.creativemedicaltechnology.com

Creative Medical Technology Holdings, Inc., a commercial stage biotechnology company, focuses on novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics in the United States. The company offers CaverStem to treat erectile dysfunction; FemCelz for the treatment of loss of genital sensitivity and dryness; and StemSpine, a regenerative stem cell procedure to treat degenerative disc disease. It also develops ImmCelz, an immunotherapy platform for multiple diseases; OvaStem for treatment of female infertility; CELZ-201 to treat Type 1 diabetes; AlloStemSpine for the treatment of chronic lower back pain; and Alova to treat infertility as a result of premature ovarian failure.

Creative Medical Technology Holdings, Inc. Fundamentals Summary

How do Creative Medical Technology Holdings's earnings and revenue compare to its market cap?
CELZ fundamental statistics
Market capUS$4.04m
Earnings (TTM)-US$5.73m
Revenue (TTM)US$17.00k

233.0x

P/S Ratio

-0.7x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
CELZ income statement (TTM)
RevenueUS$17.00k
Cost of RevenueUS$6.80k
Gross ProfitUS$10.20k
Other ExpensesUS$5.74m
Earnings-US$5.73m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-4.28
Gross Margin60.00%
Net Profit Margin-33,716.46%
Debt/Equity Ratio0.2%

How did CELZ perform over the long term?

See historical performance and comparison